Roberts labs Radinyl (etanidazole)

Roberts labs Radinyl (etanidazole): DuPont acquires North American marketing rights to the radiosensitizer agent. The new class of drugs has no direct chemotherapeutic effect but rather enhances the ability of radiation to kill cancer cells. Etanidazole was developed by the Stanford Research Institute under a grant from NCI. The products in in Phase II/III clinicals in the U.S. under sponsorship of NCI, while Roberts is funding trials in Europe. Roberts will submit the NDA in the U.S.